 |
12 Companies | 6 Products |
|
|
6 Products | |
83 Diseases | |
137 Trials |  |
14505 News |  |
| «123 |
- PTG-200 / Protagonist Therapeutics, J&J, Stelara (ustekinumab) / J&J
SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PTG-200, AN ORAL GI-RESTRICTED PEPTIDE ANTAGONIST OF IL-23 RECEPTOR, IN NORMAL HEALTHY VOLUNTEERS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2491;
PK was consistent with the GI-restricted design of PTG-200. These safety and PK characteristics, combined with fulfillment of preclinical fecal drug threshold concentrations, support further clinical development of PTG-200 for the treatment of IBD.
- PTG-200 / Protagonist Therapeutics, J&J
Safety, Tolerability, and Pharmacokinetics of PTG-200, an Oral GI-Restricted Peptide Antagonist of IL-23 Receptor, in Normal Healthy Volunteers (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_1863;
There were no serious adverse events, dose-limiting toxicities, or clinically significant adverse events. PTG-200 plasma exposure was low (Table 1), below that expected to result in systemic biological activity.
- | Stelara (ustekinumab) / J&J
Review, Journal: Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease. (Pubmed Central) - May 29, 2019
...The monoclonal antibody targeting the shared p40 subunit of IL-12 and IL23, namely ustekinumab, has been approved for Crohn's disease (CD) and has demonstrated promising results in the treatment of ulcerative colitis...Additionally, IL-12/23 and IL-23 antagonists may be preferred over anti-TNF therapy in older patients who are at increased risk for infections and malignancy. The safety compared to anti-TNF may be even greater when ones considers that concurrent immunosuppression is probably not necessary when using this class of drug, owing to the low rates of immunogenicity.